What India-EU free trade agreement means for pharma sector with access to $572.3 billion EU market?

India–EU FTA: India and the European Union on Tuesday, January 27, signed a Free Trade Agreement, formally sealing the deal after years of negotiations. The agreement is expected to ease trade between the two sides by improving market access and lowering barriers for businesses. The deal is set to benefit pharmaceutical sector of India. The deal opens the door to the EU’s large pharmaceuticals and medical devices market, giving Indian drugmakers room to expand exports and scale up operations, while strengthening India’s position as a major supplier of medicines. The agreement could also support skilled employment, boost MSME participation and improve India’s integration into global supply chains.

The government said the pact unlocks access to the European Union’s $572.3 billion pharmaceuticals and medical devices market, giving a major push to India’s pharma and MedTech sectors and opening new avenues for exports, jobs and manufacturing growth.

The announcement follows the conclusion of negotiations on the India-EU Free Trade Agreement, described by the government as a key milestone in one of India’s most strategic economic partnerships. Designed as a modern, rules-based trade pact, the agreement aims to deepen market integration between the world’s fourth- and second-largest economies while addressing current global trade challenges.

Add Zee Business as a Preferred Source

Boost for pharma, medical devices and MSMEs

According to the Ministry of Chemicals and Fertilisers, access to the vast EU market will enable Indian pharmaceutical and medical device manufacturers to scale operations, generate employment and strengthen India’s position as a reliable global supplier of medicines and healthcare products.

The ministry said the agreement is expected to expand skilled employment, increase industrial jobs, strengthen MSME participation and improve India’s integration with global supply chains, reinforcing its growing reputation as the ‘pharmacy of the world’.

Duty relief, market access for ‘Made in India’ products

Under the agreement, Indian exporters will benefit from preferential market access in high-value segments, including pharmaceuticals and medical devices. Tariffs will be liberalised for key ‘Made in India’ medical devices, helping domestic manufacturers compete more effectively in the EU market.

The FTA is also expected to drive growth across related sectors such as inorganic and organic chemicals, fertilisers, cosmetics, soaps and detergents, supporting broader capacity expansion and industrial development.

Manufacturing hubs set to gain

The government said the agreement will open major expansion opportunities across pharmaceutical and manufacturing hubs in Gujarat, Maharashtra, Karnataka and Andhra Pradesh. Coastal export hubs are expected to scale up export-led growth, supporting employment and processing-intensive industries.

Capacity expansion and MSME cluster development are seen as key outcomes of the agreement, with the ministry highlighting the potential for long-term sectoral growth.

Nadda calls FTA a major opportunity for healthcare sector

Union Minister for Chemicals and Fertilisers JP Nadda said the agreement opens new doors for the pharmaceuticals and medical devices industry. “Access to the $572.3 billion pharmaceuticals and MedTech market in the EU and liberalised tariffs for Indian medical devices will accelerate growth in this high-value sector,” Nadda said.

He added that under the leadership of Narendra Modi, India continues to strengthen its presence as a reliable global partner in healthcare manufacturing and supply.

Aligned with long-term growth vision

The ministry said the India-EU FTA aligns with India’s long-term development goals, including the vision of Viksit Bharat 2047. It reinforces shared values, promotes innovation and lays the foundation for inclusive, resilient and future-ready growth for both India and Europe.